Guo X, Xu S, Dong Z
Department of Hematology, Second Hospital, Hebei Medical University, Shijiazhuang 050000.
Zhonghua Xue Ye Xue Za Zhi. 1999 Feb;20(2):69-72.
To evaluate the value of expression of WT1 gene in predicting the prognosis of leukemia patients, and explore the relationship between WT1 gene expression and multidrug resistance and cell apoptosis.
Expressions of WT1, MRP and mdr1 were measured in 68 leukemia patients by RT-PCR method. Expression of bcl-2 was measured in 32 AML patients by immunofluorescence flow cytometry.
Expression of WT1 was revealed in 36 of 68 leukemia patients and none of 23 normal controls. Complete remission rate (59.46%) was lower in WT1 positive patients than that (87.10%, P = 0.011) in WT1 negative patients. The rate of MRP expression was also higher in patients with WT1 expression (58.33%), than in those without WT1 expression (32.26%, P = 0.033). Thirty-two AML patients were divided into high-, intermediate-, and low-risk groups according to the expression of WT1 and bcl-2. CR rates were significantly different among these 3 groups (33.33% for high-, 47.37% for intermediate-, and 100% for low-risk group, P < 0.05).
The expression of WT1 can predict the treatment outcome and the prognosis for leukemia patients. Expression of WT1 is the most important risk factor, and the coexpression of WT1 and bcl-2 predicts poor prognosis of AML patients.
评估WT1基因表达在预测白血病患者预后中的价值，并探讨WT1基因表达与多药耐药及细胞凋亡之间的关系。
采用RT-PCR法检测68例白血病患者WT1、MRP及mdr1的表达。采用免疫荧光流式细胞术检测32例急性髓系白血病（AML）患者bcl-2的表达。
68例白血病患者中有36例检测到WT1表达，23例正常对照均未检测到。WT1阳性患者的完全缓解率（59.46%）低于WT1阴性患者（87.10%，P = 0.011）。WT1表达阳性患者的MRP表达率（58.33%）也高于WT1表达阴性患者（32.26%，P = 0.033）。根据WT1和bcl-2的表达将32例AML患者分为高危、中危和低危组。这3组的完全缓解率有显著差异（高危组为33.33%，中危组为47.37%，低危组为100%，P < 0.05）。
WT1表达可预测白血病患者的治疗效果及预后。WT1表达是最重要的危险因素，WT1与bcl-2的共表达预示AML患者预后不良。
